

Review Article

Foxp3⁺ Regulatory T Cells in Mouse Models of Type 1 Diabetes

Cathleen Petzold,¹ Julia Riewaldt,¹ Deepika Watts,¹ Tim Sparwasser,²
Sonja Schallenberg,¹ and Karsten Kretschmer^{1,3}

¹Center for Regenerative Therapies Dresden, 01307 Dresden, Germany

²Institute of Infection Immunology, TWINCORE/Centre for Experimental and Clinical Infection Research, 30625 Hanover, Germany

³Paul Langerhans Institute Dresden, German Center for Diabetes Research (DZD), 01307 Dresden, Germany

Correspondence should be addressed to Karsten Kretschmer; karsten.kretschmer@crt-dresden.de

Received 21 December 2012; Accepted 3 February 2013

Academic Editor: Takahisa Yamada

Copyright © 2013 Cathleen Petzold et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Studies on human type 1 diabetes (T1D) are facilitated by the availability of animal models such as nonobese diabetic (NOD) mice that spontaneously develop autoimmune diabetes, as well as a variety of genetically engineered mouse models with reduced genetic and pathogenic complexity, as compared to the spontaneous NOD model. In recent years, increasing evidence has implicated CD4⁺CD25⁺ regulatory T (Treg) cells expressing the transcription factor Foxp3 in both the breakdown of self-tolerance and the restoration of immune homeostasis in T1D. In this paper, we provide an overview of currently available mouse models to study the role of Foxp3⁺ Treg cells in the control of destructive β cell autoimmunity, including a novel NOD model that allows specific and temporally controlled deletion of Foxp3⁺ Treg cells.

1. Introduction

Type 1 diabetes (T1D) is a chronic disease manifested by the loss of functional insulin producing β cells of pancreatic islets, caused by islet infiltrating self-reactive CD4⁺ and CD8⁺ T cells that mediate β -cell destruction [1]. Many of the immunological aspects of human T1D are mimicked by the nonobese diabetic (NOD) mouse model, which shows islet infiltration and destructive autoimmune insulinitis as early as four weeks of age and spontaneously progresses to overt diabetes in the adult [2]. Observations in mice and humans have demonstrated that CD4⁺CD25⁺ regulatory T (Treg) cells expressing the forkhead box transcription factor Foxp3 play an indispensable role in the maintenance of immune homeostasis by regulating inflammatory responses against invading pathogens and preventing destructive autoimmunity [3–6]. A particularly striking example of Foxp3⁺ Treg cell function that restrains destructive tissue-specific autoimmune responses is the observation that acute ablation of Treg cells in adult NOD mice carrying a pancreatic β cell-reactive T cell

receptor (TCR) as a transgene unleashes overt autoimmune diabetes within days (see Section 4.3). Given their nonredundant function in maintaining immune homeostasis, it is not surprising that Foxp3⁺ Treg cells have attracted considerable attention as particularly promising gain-of-function targets in clinical settings of unwanted immune responses, such as T1D. Here, we provide an overview of mouse models for T1D that, in our view, appear particularly suitable to study various aspects of Foxp3⁺ Treg cell-mediated control of β cell autoimmunity, ranging from classical diabetes models adapted to the functional analysis of Treg cells to novel genetic tools for Treg cell depletion in NOD mice.

2. Pancreatic β Cell Expression of Neo-Self-Antigens

2.1. Spontaneous Models. Double-transgenic mice that coexpress model antigens (such as ovalbumin, LCMV glycoprotein, or influenza hemagglutinin; HA) in pancreatic β cells

together with TCRs reactive to the respective β cell neo-self-antigen (either MHC class I- or class II-restricted) spontaneously develop autoimmune diabetes, recapitulating some aspects of the spontaneous NOD model, albeit with faster kinetics [8]. As an example, transgenic expression of an HA-reactive TCR on CD4⁺ (TCR-HA₁₀₇₋₁₁₉) [9, 10] or CD8⁺ (CL4-HA₅₁₂₋₅₂₀) [11] T cells promotes spontaneous diabetes development in mice that additionally express HA under control of the rat insulin promoter (RIP-HA) [12]. Potential limitations of the RIP-HA model, many of which are shared between the various double-transgenic diabetes models, have been discussed in detail elsewhere [13]. Nevertheless, TCR-HA \times RIP-HA mice offer some advantages that appear particularly relevant in the context of mechanistic studies on antigen-specific tolerance induction. While limiting β cell pathogenicity to a single, well-defined neo-self-protein, and in contrast to many other transgenic TCRs (e.g., DO11.10), the TCR-HA is expressed only on a fraction of CD4⁺ T cells (ranging from 5% to 20% in different lymphoid tissues) that coexist with polyclonal populations of TCR-HA⁻ CD4⁺ T cells expressing endogenous TCR gene rearrangements [14]. In the TCR-HA \times RIP-HA model, selective delivery of agonist ligand to steady-state DEC-205⁺ DCs has been shown to interfere with the development of autoimmune diabetes [15], probably due to the extrathymic induction of antigen-specific Foxp3⁺ Treg cells from initially naive Foxp3⁻TCR-HA⁺ T cells [16, 17]. However, it appears desirable that findings observed in double-transgenic models of spontaneous autoimmune diabetes will subsequently be extended to the nontransgenic NOD model.

2.2. Adoptive Transfer Models. In immunodeficient (Rag^{-/-}, nude) RIP-HA recipient mice, adoptive transfer of naive CD4⁺TCR-HA⁺ T cells (i.e., without prior T cell activation *in vitro*) from TCR-HA donor mice induces autoimmune diabetes within 1-2 weeks [10, 14, 18]. In immunocompetent recipient mice, naive CD4⁺TCR-HA⁺ T cell transfer (Figure 1(a)) fails to induce overt diabetes (Figure 1(c)), perhaps due to extrathymic induction of a Foxp3⁺ Treg cell phenotype in a significant proportion of initially Foxp3⁻ T cells, upon recognition of the cognate antigen on antigen-presenting cells residing in peripheral lymphoid tissues (Figure 1(b)). Notably, initially naive CD8⁺CL4⁺ [19] and CD4⁺TCR-HA⁺ (Figure 1(c)) T cells, which had been preactivated *in vitro* as previously described [7], can promote autoimmune diabetes development shortly after injection into immunocompetent recipient mice. It is important to emphasize that kinetics and efficiency of diabetes induction critically depend on suitable culture conditions for preactivation.

Double-transgenic TCR-HA \times Pkg-HA mice represent a convenient source of antigen-specific Foxp3⁺ Treg cells, as expression of HA under control of the phosphoglycerate kinase promoter (Pkg-HA) results in peripheral accumulation of intrathymically induced Foxp3⁺TCR-HA⁺ Treg cells [22]. Foxp3⁻TCR-HA⁺ T regulatory 1 cells with potent suppressor capacity can be readily isolated from peripheral lymphoid tissues of TCR-HA mice that coexpress HA under the control of the Ig- κ promoter [23]. Overall, the RIP-HA

model offers unique opportunities to study mechanisms of antigen-specific suppression of β cell autoimmunity, employing cotransfer of TCR-HA⁺ Treg cells, either with a Foxp3⁺ or Foxp3⁻ phenotype, together with pathogenic T effector cells (CD4⁺TCR-HA⁺ or CD8⁺CL4⁺).

3. NOD Adoptive Transfer Models

3.1. Adoptive BDC2.5 T Cell Transfer. CD4⁺ T cells expressing the BDC2.5 TCR as a transgene, which is reactive to islet β cells in the context of MHC class II Ag7 molecules, are highly diabetogenic in NOD mice [24, 25]. While agonistic mimotope peptides that stimulate BDC2.5⁺ T cells at nanomolar concentrations had been described some years ago [26], chromogranin A has only recently been proposed to represent the natural self-antigen responsible for pancreatic β cell pathogenicity of BDC2.5⁺ T cells [27]. Naive BDC2.5⁺ T cells, FACS purified (Figure 2(a)) from peripheral lymphoid tissues of immunocompetent NOD.BDC2.5 mice with Foxp3-dependent GFP expression (see Section 4.3) and adoptively transferred into either TCR- β ^{-/-} [28] or Rag1^{-/-} (Figure 2(b)) NOD mice, undergo lymphopenia-driven proliferation, resulting in the acquisition of a Foxp3⁺ Treg cell phenotype in a significant proportion of initially Foxp3⁻ T cells [29–31]. Nevertheless, without prior T cell activation *in vitro*, adoptive transfer of 5×10^5 naive BDC2.5⁺ T cells consistently induces autoimmune diabetes in lymphopenic NOD mice within 13.0 ± 1.2 days, as revealed by high blood glucose concentrations (Figure 2(c)). In this adoptive transfer model, autoimmune diabetes onset can be further accelerated by TCR prestimulation *in vitro* and injection of increasing numbers of BDC2.5⁺ T cells (Figure 2(c)). In fact, adoptive transfer of *in vitro* activated BDC2.5⁺ T cells into neonatal or immunodeficient (scid, TCR- β ^{-/-}, Rag1^{-/-}) NOD recipient mice is commonly used as a standard protocol for the induction of autoimmune-mediated pancreatic β islet inflammation. In contrast to T helper (Th) 2 [32] and Th17 [33] cells that had been generated from BDC2.5⁺ T cells *in vitro*, Th1-polarized BDC2.5⁺ T cells efficiently induce aggressive autoimmune diabetes upon injection into neonatal NOD mice [32], whereas Th17 BDC2.5⁺ cells have been reported to promote rapid onset of diabetes in adult NOD.scid mice [33].

In addition to providing diabetogenic CD4⁺BDC2.5⁺ T effector cells, NOD.BDC2.5 mice with Foxp3-dependent GFP expression [28, 34–37] represent a convenient source of Foxp3⁺ Treg cells with the same antigen specificity, which can be readily FACS purified (V β 4⁺CD4⁺CD25⁺GFP⁺) from CD25 bead enriched single cell suspensions of peripheral lymphoid donor tissues (Figure 3(a)). Importantly, cotransfer of as few as 5×10^4 Foxp3⁺BDC2.5⁺ Treg cells is sufficient to mediate long-term autoimmune protection of NOD.Rag1^{-/-} mice that additionally received 5×10^5 diabetogenic naive BDC2.5⁺ T cells (Figure 3(b)). Besides studies on the suppressor function of Foxp3⁺BDC2.5⁺ Treg cell populations naturally developing in NOD.BDC2.5 mice, the adoptive BDC2.5⁺ T cell transfer model provides the opportunity to assess the suppressive capacity of Foxp3⁺ Treg cells that had been artificially generated from initially Foxp3⁻ BDC2.5⁺ T cells




FIGURE 1: Adoptive TCR-HA⁺ T cell transfer into immunocompetent RIP-HA mice. (a) Using the clonotypic antibody 6.5, naïve TCR-HA⁺ T cells (CD4⁺6.5⁺CD62L^{high}CD25⁻GFP⁻) were FACS purified from BALB/c.Thy1.1 TCR-HA × Foxp3^{IRES-GFP} mice, after CD4 bead enrichment of pooled cells from spleen and LNs. Presort (top) and postsort (bottom) analyses of TCR-HA/CD62L (left) and CD25/GFP (right) expression among CD4-gated cells are depicted. The gating scheme is illustrated by the line with arrowhead. For antigen-specific stimulation *in vitro*, TCR-HA⁺ T cells were cultured as previously described [7], in the presence of HA₁₀₇₋₁₁₉ peptide (10 μg/mL). As indicated, naïve or *in vitro* preactivated TCR-HA⁺ T cells were injected i.v. into immunocompetent BALB/c.Thy1.2 RIP-HA mice. (b) Flow cytometry of Foxp3^{IRES-GFP} expression among gated CD4⁺Thy1.1⁺ cells at day 14 after adoptive transfer into BALB/c.RIP-HA recipient mice (mLN: mesenteric lymph node; pLN: pancreatic LN). Numbers in dot plots or histograms indicate the percentage of cells in the respective gate. (c) Blood glucose concentrations (top) and diabetes incidence (bottom) of BALB/c.RIP-HA mice injected with naïve (blue circles, *n* = 5) or *in vitro* preactivated TCR-HA⁺ T cells (red circles, *n* = 5). Blood glucose concentrations (in mg/dL) of individual mice were determined every other day and plotted against time. The grey dashed line indicates normoglycemia. Mice were considered diabetic at blood glucose levels above 200 mg/dL (red dashed line) on at least two consecutive measurements or with blood glucose levels once above 400 mg/dL.

in experimental settings of extrathymic Treg cell induction, for example, by retrovirus-mediated ectopic expression of Foxp3 (Figure 3(c)). Note that, as compared to the adoptive transfer of naïve BDC2.5⁺ T cells alone (Figure 3(b)), cotransfer of [Empty]-IRES-YFP⁺ BDC2.5⁺ T cells substantially accelerates diabetes due to T cell prestimulation *in vitro* for retrovirus infection (Figure 3(c)).

In immunocompetent NOD mice, the *in vivo* application of *in vitro* expanded Foxp3⁺BDC2.5⁺ Treg cells [38, 39], as well as Foxp3⁺BDC2.5⁺ Treg cells, generated *in vitro* either by

ectopic expression of Foxp3 [20] or TGF-β-mediated induction of Foxp3 expression [40], can be effective in prevention or even reversal of spontaneously developing diabetes.

3.2. Adoptive Transfer of Polyclonal T Cells. Unfractionated splenocytes from diabetic, non-TCR transgenic NOD donor mice can induce autoimmune diabetes within 3 weeks after injection into immunodeficient NOD mice, such as NOD.Rag1^{-/-} mice (Figure 3(d)) or irradiated NOD mice [41]. Although the relative contribution of CD4⁺ and CD8⁺ T




FIGURE 2: Adoptive BDC2.5⁺ T cell transfer into immunodeficient NOD mice. (a) Using anti-Vβ4 antibodies, naïve BDC2.5⁺ T cells (CD4⁺Vβ4⁺CD62L^{high}CD25⁻GFP⁻) were FACS purified from NOD.Foxp3^{DTR-GFP} × BDC2.5 mice, after CD4 bead enrichment of pooled cells from spleen and LNs. Presort (top) and postsort (bottom) analyses of Vβ4/CD62L (left) and CD25/GFP (right) expression among CD4-gated cells are depicted. The gating scheme is illustrated by the line with arrowhead. For antigen-specific stimulation *in vitro*, BDC2.5⁺ T cells were cultured as previously described [7], in the presence of the mimotope peptide RTRPLWVRME (10 μg/mL). Naïve or *in vitro* preactivated BDC2.5⁺ T cells were injected *i.v.* into NOD.Rag1^{-/-} recipient mice, as indicated below. (b) Flow cytometry of GFP (left) and CD25/GFP (right) expression among gated CD4⁺ cells from LNs at day 15 after adoptive transfer into NOD.Rag1^{-/-} recipient mice. Numbers in dot plots indicate the percentage of cells in the respective quadrant or gate. (c) Blood glucose concentrations (top) and diabetes incidence (bottom) of NOD.Rag1^{-/-} recipient mice injected with naïve (5 × 10⁵ cells/mouse, blue triangles, *n* = 4) or *in vitro* preactivated BDC2.5⁺ T cells (5 × 10⁵ cells/mouse, red squares, *n* = 4; or 6 × 10⁶ cells/mouse, red circles, *n* = 3). Blood glucose concentrations of recipient mice were determined and plotted as described in the legend for Figure 1.

cells had remained controversial in previous studies [42, 43], more recent observations in NOD.scid mice using highly purified T cell populations revealed that the development of autoimmune diabetes in this adoptive transfer model requires both CD4⁺ and CD8⁺ T cells [44]. Cotransfer of polyclonal Foxp3⁺ Treg cells, either purified populations or contained in unfractionated total cell populations, can be employed to assess their suppressive capacity in the context of autoimmune diabetes. After tolerogenic DEC-205⁺ dendritic cell vaccination to promote proinsulin-reactive Foxp3⁺ Treg cell activity, cotransfer of total spleen cells from autoimmune protected NOD donors can delay the onset of diabetogenic

splenocyte-mediated diabetes in NOD.Rag1^{-/-} recipients (Figure 3(d)) [21].

4. Abrogation of Foxp3⁺ Treg Cell Activity

4.1. Genetic Deficiency. Abrogated Treg cell function has been actively debated as a putative mechanism underlying various autoimmune disorders in humans [45]. The important role of Foxp3⁺ Treg cells in protection from autoimmune diabetes is highlighted by the notion that T1D represents a major component of the IPEX (immune dysfunction,




FIGURE 3: Foxp3⁺ Treg cells in NOD transfer models. (a–c) Adoptive BDC2.5⁺ T cell transfer. (a) FACS purification of BDC2.5⁺Foxp3⁺ Treg cells (CD4⁺Vβ4⁺CD25⁺GFP⁺) from pooled spleen and LNs of NOD.Foxp3^{Cre-GFP} × BDC2.5 mice after magnetic bead enrichment of CD25⁺ cells. Presort (top) and postsort (bottom) analyses of CD4/Vβ4 (left) and CD25/GFP (right) expression among gated lymphocytes are depicted. The gating scheme is illustrated by the line with arrowhead. Numbers in dot plots indicate the percentage of cells in the respective gate. (b) For diabetes induction, NOD.Rag1^{-/-} recipient mice were injected with naïve BDC2.5⁺ T cells (5 × 10⁵ cells/mouse), either alone (red circles, n = 5) or coinjected with Foxp3⁺BDC2.5⁺ Treg cells (5 × 10⁴ cells/mouse, blue circles, n = 5) that had been FACS purified as shown in (a). See Figure 2(a) for details on the flow cytometric isolation of naïve BDC2.5⁺ T cells. (c) In addition to naïve BDC2.5⁺ T cells (5 × 10⁵ cells/mouse), NOD.Rag1^{-/-} recipient mice were coinjected with 1 × 10⁵ BDC2.5⁺ T cells that exhibited retrovirus-mediated expression of either [Empty]-IRES-YFP (red circles, n = 3) or [Foxp3]-IRES-YFP (blue circles, n = 3). Retrovirus infections of initially naïve, TCR stimulated BDC2.5⁺ T cells were performed essentially as described previously [20]. (d) Adoptive transfer of polyclonal T cells. NOD.Rag1^{-/-} recipient mice received splenocytes harvested from diabetic NOD donor mice (red circles, n = 6, average diabetes development at day 21.8 ± 2.6) or were coinjected with equivalent numbers of splenocytes from NOD donors that maintained normoglycemia until 26 weeks of age after treatment with recombinant anti-DEC-205 antibodies fused to whole proinsulin, beginning at 7 weeks of age (blue circles, n = 3, average diabetes development at day 33.0 ± 0.8) (adopted from [21]). Blood glucose concentrations of recipient mice in (b–d) were determined and plotted as described in the legend for Figure 1.




FIGURE 4: Fcpx3⁺ Treg cell ablation in NOD.Fcpx3^{DTR-GFP} mice. (a) Percentage of Fcpx3^{DTR-GFP} cells among CD4⁺ T cells in subcutaneous lymph nodes (scLN, top) and pancreatic LNs (pLN, bottom) of NOD.Fcpx3^{DTR-GFP} × BDC2.5 mice, which were either left untreated (dashed line) or i.p. injected with DT (0.5 µg/mouse on 3 consecutive days). Symbols represent individual mice at indicated time points after the first DT administration. (b) Blood glucose concentrations and (c) diabetes incidence of NOD.Fcpx3^{DTR-GFP} mice (blue triangles: females, $n = 11$; blue circles: males, $n = 11$) and NOD.Fcpx3^{DTR-GFP} × BDC2.5 mice (red triangles: females, $n = 9$; red circles: males, $n = 12$), after DT administration, as indicated by the arrowheads.

polyendocrinopathy, enteropathy, X-linked) syndrome [46–48] that affects humans with abrogated Treg cell function due to mutations in the FOXP3 gene [49–51]. In mice, spontaneous [52] or gene-targeted [53] Fcpx3 deficiency leads to death by 3–4 weeks of age due to the development of a fatal multiorgan autoimmune syndrome that recapitulates many clinical features of the human IPEX syndrome. Notably, the manifestation of autoimmune diabetes in Fcpx3-deficient mice on non-autoimmune-prone genetic backgrounds has not been reported thus far. Moreover, Fcpx3-deficient mice on the diabetes-prone NOD background develop exocrine

pancreatitis and peri-insulinitis, but do not manifest invasive insulinitis and diabetes [54]. Several nonmutually exclusive mechanisms may account for the absence of overt diabetes in Fcpx3-deficient mice, which includes premature death and altered T cell repertoire selection due to severe defects in thymic T cell development [55]. In any case, this striking difference to human IPEX patients regarding the manifestation of autoimmune diabetes limits the exploitation of mice with constitutive genetic Fcpx3 deficiency and concomitant absence of functional Treg cells in studies on pancreatic β cell autoimmunity.

4.2. Administration of Anti-CD25 mAbs. To examine the contribution of Foxp3⁺ Treg cells in the control of pancreatic β cell autoimmunity, administration of anti-CD25 mAbs has been widely used as a loss-of-function approach, with the overwhelming majority of studies employing the clone PC61 (rather than 7D4). Whether abrogation of suppressor activity upon *in vivo* administration of anti-CD25 mAbs can be attributed to the functional inactivation [56] or the actual physical elimination (deletion) of CD25-expressing Foxp3⁺ Treg cells has been controversially discussed [56–58]. In otherwise nonmanipulated NOD mice, single dose [59] or repeated [60] injection of the anti-CD25 mAb PC61 can significantly accelerate the spontaneous development of autoimmune diabetes in adolescent but not adult [61] females. In experimental settings of tolerogenic regimens that result in long-term protection of NOD mice from autoimmune β cell destruction, anti-CD25 mAbs have been employed as an approach to address the relative contribution of CD25⁺ Treg cells in tolerance induction, with PC61 administration resulting either in the rapid precipitation of overt diabetes [59, 61–63] or the failure to break established β cell tolerance and maintenance of normoglycemia [64–66]. However, interpretation of results from such experiments is hampered by the fact that CD25 expression is not exclusive to Foxp3⁺ Treg cells. In fact, PC61 administration to adult NOD mice has also been reported to delay diabetes onset [65], perhaps due to its negative impact on activated CD4⁺ and CD8⁺ T effector cells with upregulated CD25 expression. Additionally, it appears important to emphasize that anti-CD25 treatment with the aim to interfere with Treg cell function, either by deletion or functional inactivation, will inevitably spare Foxp3⁺ Treg cells with a CD25^{low/-} phenotype. Consistently, anti-CD25 treatment protocols preserve significant numbers of Foxp3⁺ cells [56–58, 67, 68].

4.3. Diphtheria Toxin-Mediated Deletion of Foxp3⁺ Treg Cells. Foxp3-dependent expression of the human diphtheria toxin (DT) receptor as a transgene, either from an internal ribosome entry site (IRES) downstream of the Foxp3 coding region [69] or from a Foxp3 bacterial artificial chromosome (BAC) (termed “depletion of regulatory T cell” mice, DEREg; [36]), provides an opportunity for specific and temporally controlled deletion of Foxp3⁺ Treg cells in mice on non-autoimmune-prone genetic backgrounds. In both mouse models, Foxp3⁺ Treg cell depletion by the *in vivo* administration of DT promotes the development of autoimmune disorders, albeit with differences in the severity of autoimmune symptoms [36, 69]. On the NOD genetic background, two independent mouse lines with DT receptor expression selectively in Foxp3⁺ Treg cells have been generated. While Feuerer et al. established a novel Foxp3 BAC transgenic line employing NOD embryos [28], we generated NOD.Foxp3^{DTR-GFP} mice by backcrossing the BAC-Foxp3^{DTR-GFP} transgene of the well-characterized DEREg mouse model [36, 70–73] onto the NOD/Lt background (Figure 4).

Transgenic expression of the BDC2.5 TCR efficiently prevents the development of spontaneous autoimmune diabetes

in immunocompetent NOD females [74] but dramatically accelerates diabetes progression in immunodeficient NOD mice, such as NOD.TCR- $\beta^{-/-}$ or NOD.Rag1^{-/-} mice [74], as well as in NOD.Foxp3^{-/-} mice [54]. Acute ablation of Foxp3⁺ Treg cells (Figure 4(a)) can lead to transiently increased blood glucose concentration in some adult NOD.Foxp3^{DTR-GFP} females, but fails to consistently promote overt diabetes (Figure 4(b)). In NOD.Foxp3^{DTR-GFP} \times BDC2.5 females, Foxp3⁺ Treg cell ablation triggers autoimmune β cell destruction within 8 days after initiation of DT administration (Figure 4(b)). Notably, and in contrast to the spontaneous NOD model, the NOD.Foxp3^{DTR-GFP} \times BDC2.5 model additionally allows the induction of autoimmune diabetes in male mice, with similar efficiency and kinetics as compared to females (Figure 4(c)).

Conflict of Interests

The authors declare that there is no conflict of interests.

Acknowledgments

This work was supported by the Kompetenznetz Diabetes mellitus (Competence Network for Diabetes mellitus) funded by the Federal Ministry of Education and Research (FKZ 01GI0805-07) by a grant from the BMBF to the German Center for Diabetes Research (DZD e.V., FKZ01GI0924) and by the FZT III (DFG, Center for Regenerative Therapies Dresden, Cluster of Excellence).

References

- [1] H. O. McDevitt and E. R. Unanue, “Autoimmune diabetes mellitus—much progress, but many challenges,” *Advances in Immunology*, vol. 100, pp. 1–12, 2008.
- [2] M. S. Anderson and J. A. Bluestone, “The NOD mouse: a model of immune dysregulation,” *Annual Review of Immunology*, vol. 23, pp. 447–485, 2005.
- [3] S. Sakaguchi, M. Ono, R. Setoguchi et al., “Foxp3⁺CD25⁺CD4⁺ natural regulatory T cells in dominant self-tolerance and autoimmune disease,” *Immunological Reviews*, vol. 212, pp. 8–27, 2006.
- [4] S. Sakaguchi, T. Yamaguchi, T. Nomura, and M. Ono, “Regulatory T cells and immune tolerance,” *Cell*, vol. 133, no. 5, pp. 775–787, 2008.
- [5] K. Wing and S. Sakaguchi, “Regulatory T cells exert checks and balances on self tolerance and autoimmunity,” *Nature Immunology*, vol. 11, no. 1, pp. 7–13, 2010.
- [6] G. Kassiotis, A. Liston, and S. Sakaguchi, “Regulatory T cells: history and perspective,” in *Regulatory T Cells*, pp. 3–17, Humana Press, 2011.
- [7] B. T. Fife, I. Guleria, M. G. Bupp et al., “Insulin-induced remission in new-onset NOD mice is maintained by the PD-1/PD-L1 pathway,” *Journal of Experimental Medicine*, vol. 203, no. 12, pp. 2737–2747, 2006.
- [8] T. L. Van Belle, P. Taylor, and M. G. von Herrath, “Mouse models for type 1 diabetes,” *Drug Discovery Today*, vol. 6, no. 2, pp. 41–45, 2009.

- [9] A. Sarukhan, A. Lanoue, A. Franzke, N. Brousse, J. Buer, and H. Von Boehmer, "Changes in function of antigen-specific lymphocytes correlating with progression towards diabetes in a transgenic model," *The EMBO Journal*, vol. 17, no. 1, pp. 71–80, 1998.
- [10] I. Apostolou, Z. Hao, K. Rajewsky, and H. Von Boehmer, "Effective destruction of Fas-deficient insulin-producing β cells in type 1 diabetes," *Journal of Experimental Medicine*, vol. 198, no. 7, pp. 1103–1106, 2003.
- [11] D. J. Morgan, R. Liblau, B. Scott et al., "CD8⁺ T cell-mediated spontaneous diabetes in neonatal mice," *The Journal of Immunology*, vol. 157, no. 3, pp. 978–983, 1996.
- [12] D. Lo, J. Freedman, S. Hesse, R. D. Palmiter, R. L. Brinster, and L. A. Sherman, "Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4⁺ and CD8⁺ T cells," *European Journal of Immunology*, vol. 22, no. 4, pp. 1013–1022, 1992.
- [13] I. Apostolou and H. Von Boehmer, "The TCR-HA, INS-HA transgenic model of autoimmune diabetes: limitations and expectations," *Journal of Autoimmunity*, vol. 22, no. 2, pp. 111–114, 2004.
- [14] A. Sarukhan, C. Garcia, A. Lanoue, and H. Von Boehmer, "Allelic inclusion of T cell receptor α genes poses an autoimmune hazard due to low-level expression of autospecific receptors," *Immunity*, vol. 8, no. 5, pp. 563–570, 1998.
- [15] D. Bruder, A. M. Westendorf, W. Hansen et al., "On the edge of autoimmunity: T cell stimulation by steady-state dendritic cells prevents autoimmune diabetes," *Diabetes*, vol. 54, no. 12, pp. 3395–3401, 2005.
- [16] K. Kretschmer, I. Apostolou, D. Hawiger, K. Khazaie, M. C. Nussenzweig, and H. von Boehmer, "Inducing and expanding regulatory T cell populations by foreign antigen," *Nature Immunology*, vol. 6, no. 12, pp. 1219–1227, 2005.
- [17] K. Kretschmer, T. S. P. Heng, and H. von Boehmer, "De novo production of antigen-specific suppressor cells *in vivo*," *Nature Protocols*, vol. 1, no. 2, pp. 653–661, 2006.
- [18] A. Sarukhan, O. Lechner, and H. von Boehmer, "Autoimmune insulinitis and diabetes in the absence of antigen-specific contact between T cells and β -islet cells," *European Journal of Immunology*, vol. 29, no. 10, pp. 3410–3416, 1999.
- [19] C. Vizler, N. Bercovici, A. Heurtier et al., "Relative diabetogenic properties of islet-specific Tc1 and Tc2 cells in immunocompetent hosts," *The Journal of Immunology*, vol. 165, no. 11, pp. 6314–6321, 2000.
- [20] E. Jaekel, H. Von Boehmer, and M. P. Manns, "Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes," *Diabetes*, vol. 54, no. 2, pp. 306–310, 2005.
- [21] C. Petzold, J. Riewaldt, T. Koenig, S. Schallenberg, and K. Kretschmer, "Dendritic cell-targeted pancreatic beta-cell antigen leads to conversion of self-reactive CD4⁺ T cells into regulatory T cells and promotes immunotolerance in NOD mice," *The Review of Diabetic Studies*, vol. 7, no. 1, pp. 47–61, 2010.
- [22] L. Klein, K. Khazaie, and H. Von Boehmer, "In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior *in vitro*," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 15, pp. 8886–8891, 2003.
- [23] W. Hansen, A. M. Westendorf, S. Reinwald et al., "Chronic antigen stimulation *in vivo* induces a distinct population of antigen-specific Foxp3⁺ CD25⁺ regulatory T cells," *The Journal of Immunology*, vol. 179, no. 12, pp. 8059–8068, 2007.
- [24] J. D. Katz, B. Wang, K. Haskins, C. Benoist, and D. Mathis, "Following a diabetogenic T cell from genesis through pathogenesis," *Cell*, vol. 74, no. 6, pp. 1089–1100, 1993.
- [25] K. Haskins, M. Portas, B. Bradley, D. Wegmann, and K. Lafferty, "T-lymphocyte clone specific for pancreatic islet antigen," *Diabetes*, vol. 37, no. 10, pp. 1444–1448, 1988.
- [26] V. Judkowski, C. Pinilla, K. Schroder, L. Tucker, N. Sarvetnick, and D. B. Wilson, "Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice," *The Journal of Immunology*, vol. 166, no. 2, pp. 908–917, 2001.
- [27] B. D. Stadinski, T. Delong, N. Reisdorph et al., "Chromogranin A is an autoantigen in type 1 diabetes," *Nature Immunology*, vol. 11, no. 3, pp. 225–231, 2010.
- [28] M. Feuerer, Y. Shen, D. R. Littman, C. Benoist, and D. Mathis, "How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets," *Immunity*, vol. 31, no. 4, pp. 654–664, 2009.
- [29] M. A. Curotto De Lafaille, A. C. Lino, N. Kutchukhidze, and J. J. Lafaille, "CD25⁺ T cells generate CD25⁺ Foxp3⁺ regulatory T cells by peripheral expansion," *The Journal of Immunology*, vol. 173, no. 12, pp. 7259–7268, 2004.
- [30] D. Haribhai, W. Lin, B. Edwards et al., "A central role for induced regulatory T cells in tolerance induction in experimental colitis," *The Journal of Immunology*, vol. 182, no. 6, pp. 3461–3468, 2009.
- [31] B. Knoechel, J. Lohr, E. Kahn, J. A. Bluestone, and A. K. Abbas, "Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen," *Journal of Experimental Medicine*, vol. 202, no. 10, pp. 1375–1386, 2005.
- [32] J. D. Katz, C. Benoist, and D. Mathis, "T helper cell subsets in insulin-dependent diabetes," *Science*, vol. 268, no. 5214, pp. 1185–1188, 1995.
- [33] N. Martin-Orozco, Y. Chung, S. H. Chang, Y. H. Wang, and C. Dong, "Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells," *European Journal of Immunology*, vol. 39, no. 1, pp. 216–224, 2009.
- [34] M. L. Bettini, F. Pan, M. Bettini et al., "Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency," *Immunity*, vol. 36, no. 5, pp. 717–730, 2012.
- [35] J. Darce, D. Rudra, L. Li et al., "An N-terminal mutation of the Foxp3 transcription factor alleviates arthritis but exacerbates diabetes," *Immunity*, vol. 36, no. 5, pp. 731–741, 2012.
- [36] K. Lahl, C. Loddenkemper, C. Drouin et al., "Selective depletion of Foxp3⁺ regulatory T cells induces a scurfy-like disease," *Journal of Experimental Medicine*, vol. 204, no. 1, pp. 57–63, 2007.
- [37] X. Zhou, L. T. Jeker, B. T. Fife et al., "Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity," *Journal of Experimental Medicine*, vol. 205, no. 9, pp. 1983–1991, 2008.
- [38] K. V. Tarbell, L. Petit, X. Zuo et al., "Dendritic cell-expanded, islet-specific CD4⁺ CD25⁺ CD62L⁺ regulatory T cells restore normoglycemia in diabetic NOD mice," *Journal of Experimental Medicine*, vol. 204, no. 1, pp. 191–201, 2007.
- [39] K. V. Tarbell, S. Yamazaki, K. Olson, P. Toy, and R. M. Steinman, "CD25⁺ CD4⁺ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes," *Journal of Experimental Medicine*, vol. 199, no. 11, pp. 1467–1477, 2004.

- [40] X. Luo, K. V. Tarbell, H. Yang et al., "Dendritic cells with TGF- β 1 differentiate naive CD4⁺CD25⁻ T cells into islet-protective Foxp3⁺ regulatory T cells," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 8, pp. 2821–2826, 2007.
- [41] P. R. Hutchings and A. Cooke, "The transfer of autoimmune diabetes in NOD mice can be inhibited or accelerated by distinct cell populations present in normal splenocytes taken from young males," *Journal of Autoimmunity*, vol. 3, no. 2, pp. 175–185, 1990.
- [42] B. J. Miller, M. C. Appel, J. J. O'Neil, and L. S. Wicker, "Both the L γ T-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice," *The Journal of Immunology*, vol. 140, no. 1, pp. 52–58, 1988.
- [43] S. W. Christianson, L. D. Shultz, and E. H. Leiter, "Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice: relative contributions of CD4⁺ and CD8⁺ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors," *Diabetes*, vol. 42, no. 1, pp. 44–55, 1993.
- [44] J. M. Phillips, N. M. Parish, T. Raine et al., "Type 1 diabetes development requires both CD4⁺ and CD8⁺ T cells and can be reversed by non-depleting antibodies targeting both T cell populations," *Review of Diabetic Studies*, vol. 6, no. 2, pp. 97–103, 2009.
- [45] M. Miyara, G. Gorochov, M. Ehrenstein et al., "Human Foxp3⁺ regulatory T cells in systemic autoimmune diseases," *Autoimmunity Reviews*, vol. 10, no. 12, pp. 744–755, 2011.
- [46] D. Moraes-Vasconcelos, B. T. Costa-Carvalho, T. R. Torgerson, and H. D. Ochs, "Primary immune deficiency disorders presenting as autoimmune diseases: IPEX and APECED," *Journal of Clinical Immunology*, vol. 28, no. 1, pp. S11–S19, 2008.
- [47] T. R. Torgerson and H. D. Ochs, "Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells," *The Journal of Allergy and Clinical Immunology*, vol. 120, no. 4, pp. 744–750, 2007.
- [48] R. S. Wildin, S. Smyk-Pearson, and A. H. Filipovich, "Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome," *Journal of Medical Genetics*, vol. 39, no. 8, pp. 537–545, 2002.
- [49] T. A. Chatila, F. Blaeser, N. Ho et al., "JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic dysregulation syndrome," *The Journal of Clinical Investigation*, vol. 106, no. 12, pp. R75–R81, 2000.
- [50] C. L. Bennett, J. Christie, F. Ramsdell et al., "The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3," *Nature Genetics*, vol. 27, no. 1, pp. 20–21, 2001.
- [51] R. S. Wildin, F. Ramsdell, J. Peake et al., "X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy," *Nature Genetics*, vol. 27, no. 1, pp. 18–20, 2001.
- [52] M. E. Brunkow, E. W. Jeffery, K. A. Hjerrild et al., "Disruption of a new forkhead/winged-helix protein, scurfy, results in the fatal lymphoproliferative disorder of the scurfy mouse," *Nature Genetics*, vol. 27, no. 1, pp. 68–73, 2001.
- [53] J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, "Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells," *Nature Immunology*, vol. 4, no. 4, pp. 330–336, 2003.
- [54] Z. Chen, A. E. Herman, M. Matos, D. Mathis, and C. Benoist, "Where CD4⁺CD25⁺ T reg cells impinge on autoimmune diabetes," *Journal of Experimental Medicine*, vol. 202, no. 10, pp. 1387–1397, 2005.
- [55] J. Riewaldt, S. Dueber, M. Boernert et al., "Severe developmental B lymphopoietic defects in Foxp3-deficient mice are refractory to adoptive regulatory T cell therapy," *Frontiers in Immunology*, vol. 3, article 141, 2012.
- [56] A. P. Kohm, J. S. McMahon, J. R. Podojil et al., "Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4⁺CD25⁺ T regulatory cells," *The Journal of Immunology*, vol. 176, no. 6, pp. 3301–3305, 2006.
- [57] L. A. Stephens and S. M. Anderton, "Comment on 'Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4⁺CD25⁺ T regulatory cells,'" *The Journal of Immunology*, vol. 177, no. 4, article 2036, 2006.
- [58] S. Zelenay and J. Demengeot, "Comment on 'Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4⁺CD25⁺ T regulatory cells,'" *The Journal of Immunology*, vol. 177, no. 4, pp. 2036–2037, 2006.
- [59] K. Fukushima, N. Abiru, Y. Nagayama et al., "Combined insulin B:9-23 self-peptide and polyinosinic-polycytidylic acid accelerate insulinitis but inhibit development of diabetes by increasing the proportion of CD4⁺Foxp3⁺ regulatory T cells in the islets in non-obese diabetic mice," *Biochemical and Biophysical Research Communications*, vol. 367, no. 4, pp. 719–724, 2008.
- [60] R. J. Mellanby, D. Thomas, J. M. Phillips, and A. Cooke, "Diabetes in non-obese diabetic mice is not associated with quantitative changes in CD4⁺CD25⁺Foxp3⁺ regulatory T cells," *Immunology*, vol. 121, no. 1, pp. 15–28, 2007.
- [61] E. Mariño, J. Villanueva, S. Walters, D. Liuwantara, F. Mackay, and S. T. Grey, "CD4⁺CD25⁺ T-cells control autoimmunity in the absence of B-cells," *Diabetes*, vol. 58, no. 7, pp. 1568–1577, 2009.
- [62] D. Ly, Q. S. Mi, S. Hussain, and T. L. Delovitch, "Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4⁺CD25⁺ regulatory T cells," *The Journal of Immunology*, vol. 177, no. 6, pp. 3695–3704, 2006.
- [63] F. Billiard, C. Lobry, G. Darrasse-Jeze et al., "Dll4-Notch signaling in Flt3-independent dendritic cell development and autoimmunity in mice," *The Journal of Experimental Medicine*, vol. 209, no. 5, pp. 1011–1028, 2012.
- [64] X. Luo, K. L. Pothoven, D. McCarthy et al., "ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 38, pp. 14527–14532, 2008.
- [65] M. P. Huebner, Y. Shi, M. N. Torrero et al., "Helminth protection against autoimmune diabetes in nonobese diabetic mice is independent of a type 2 immune shift and requires TGF- β ," *The Journal of Immunology*, vol. 188, no. 2, pp. 559–568, 2012.
- [66] Q. Liu, K. Sundar, P. K. Mishra et al., "Helminth infection can reduce insulinitis and type 1 diabetes through CD25- and IL-10-independent mechanisms," *Infection and Immunity*, vol. 77, no. 12, pp. 5347–5358, 2009.
- [67] K. Minamimura, W. Gao, and T. Maki, "CD4⁺ regulatory T cells are spared from deletion by antilymphocyte serum, a polyclonal anti-T cell antibody," *The Journal of Immunology*, vol. 176, no. 7, pp. 4125–4132, 2006.
- [68] P. E. Fecci, A. E. Sweeney, P. M. Grossi et al., "Systemic anti-CD25 monoclonal antibody administration safely enhances

- immunity in murine glioma without eliminating regulatory T cells,” *Clinical Cancer Research*, vol. 12, no. 14, pp. 4294–4305, 2006.
- [69] J. M. Kim, J. P. Rasmussen, and A. Y. Rudensky, “Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice,” *Nature Immunology*, vol. 8, no. 2, pp. 191–197, 2007.
- [70] S. Schallenberg, C. Petzold, P.-Y. Tsai, T. Sparwasser, and K. Kretschmer, “Vagaries of fluorochrome reporter gene expression in Foxp3⁺ regulatory T cells,” *PLoS ONE*, vol. 7, no. 8, Article ID e41971, 2012.
- [71] A. M. Baru, C. Untucht, V. Ganesh et al., “Optimal isolation of functional Foxp3⁺ induced regulatory T cells using DERE mice,” *PLoS ONE*, vol. 7, no. 9, Article ID e44760, 2012.
- [72] K. Lahl and T. Sparwasser, “*In vivo* depletion of Foxp3⁺ Tregs using the DERE mouse model,” *Methods in Molecular Biology*, vol. 707, pp. 157–172, 2011.
- [73] J. Kim, K. Lahl, S. Hori et al., “Cutting edge: depletion of Foxp3⁺ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice,” *The Journal of Immunology*, vol. 183, no. 12, pp. 7631–7634, 2009.
- [74] S. You, G. Slehoffer, S. Barriot, J. F. Bach, and L. Chatenoud, “Unique role of CD4⁺CD62L⁺ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, supplement 2, pp. 14580–14585, 2004.